Skip to main content

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Mònica Pons Delgado

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Determinación de biomarcadores de lesión neuronal y astrocitaria en suero de paciente con encefalopatía hepática

IP: Macarena Simon-Talero Horga
Collaborators: Joaquin Castillo Justribo, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 60500
Reference: PI21/00312
Duration: 01/01/2022 - 31/12/2024

OPTIMIZACIÓN DE NUEVOS TRATAMIENTOS EN LA ENFERMEDAD HEPÁTICA CRÓNICA-NASH

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Maria Nieves Martell Pérez-Alcalde, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 268620
Reference: PI21/00691
Duration: 01/01/2022 - 30/06/2026

pendent

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR21/00064
Duration: 01/01/2022 - 31/12/2025

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Maria Francesca Eugenia Filippi Arriaga

Maria Francesca Eugenia Filippi Arriaga

Research technician
Clinical Pharmacology
Read more
Rafael Oleo Taltavull

Rafael Oleo Taltavull

Main researcher
Reconstructive Surgery of the Locomotor System
Read more
Mireya Torres Moliner

Mireya Torres Moliner

Predoctoral researcher
Growth and Development
Read more
Cocera Rodríguez Raúl

Cocera Rodríguez Raúl

Research technician
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.